During the past decade, The Urology Group conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "The Urology Group" are "Cystitis, Interstitial" (2 trials) and "Interstitial Cystitis" (1 trials). Many other conditions were trialed in "The Urology Group" in a lesser frequency.

Most popular intervention types in "The Urology Group" are "Drug" (2 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "MN-001" (1 trials), "MN-001 BID" (1 trials), "PF-04383119" (1 trials) and "Tanezumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "The Urology Group" are 3 trials for "All" genders.

Currently, there are NaN active trials in "The Urology Group". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in The Urology Group, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in The Urology Group, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".